Loan Hoang-Sayag
Direktor/Vorstandsmitglied bei Orano Med SAS
Aktive Positionen von Loan Hoang-Sayag
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Andera Partners SCA
Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Private Equity Investor | 01.11.2018 | - |
Orano Med SAS
Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Loan Hoang-Sayag
Ehemalige bekannte Positionen von Loan Hoang-Sayag
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CELLECTIS S.A. | Technik-/Wissenschafts-/F&E-Leiter | 08.01.2016 | 05.10.2017 |
MEDIAN TECHNOLOGIES | Technik-/Wissenschafts-/F&E-Leiter | 26.10.2017 | - |
Quintiles Transnational Corp.
Quintiles Transnational Corp. Miscellaneous Commercial ServicesCommercial Services Quintiles Transnational Corp. provides biopharmaceutical development and commercial outsourcing services. It offers product development and integrated healthcare services, including commercial and observational solutions. The company was founded by Dennis B. Gillings and Gary Koch in September 1990 and is headquartered in Durham, NC. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von Loan Hoang-Sayag
Sorbonne Université | Graduate Degree |
Statistik
International
Frankreich | 6 |
Vereinigte Staaten | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 3 |
Private Equity Investor | 1 |
Graduate Degree | 1 |
Sektoral
Health Technology | 3 |
Commercial Services | 2 |
Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
CELLECTIS S.A. | Health Technology |
MEDIAN TECHNOLOGIES | Health Services |
Private Unternehmen | 3 |
---|---|
Quintiles Transnational Corp.
Quintiles Transnational Corp. Miscellaneous Commercial ServicesCommercial Services Quintiles Transnational Corp. provides biopharmaceutical development and commercial outsourcing services. It offers product development and integrated healthcare services, including commercial and observational solutions. The company was founded by Dennis B. Gillings and Gary Koch in September 1990 and is headquartered in Durham, NC. | Commercial Services |
Andera Partners SCA
Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Finance |
Orano Med SAS
Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | Health Technology |
- Börse
- Insiders
- Loan Hoang-Sayag
- Erfahrung